The PHARMO Institute is an internationally recognised organisation, dedicated to the improvement of the use, quality and cost-effectiveness of pharmaceuticals. We collect, maintain and perform research on patient-centric data to derive real-life insights for tailoring of medicines. 


PHARMO attended the ISPOR 18th Annual European Congress

International multi-database study published in The European Journal of Contraception & Reproductive Health Care

Study in the field of mother and child health published in Acta Paediatrica: Infants born before 32 weeks of gestation or with respiratory disease are most likely to receive palivizumab in the Netherlands

Sign up to the PHARMO newsletter